A3-APO

O=C([C@@H](NC(C1(CCCCC1)N)=O)CCCNC(N)=N)N2[C@H](C(N[C@H](C(N[C@H](C(N3[C@H](C(N[C@H](C(N4[C@H](C(N[C@H](C(N[C@H](C(N5[C@H](C(N[C@H](C(N6[C@H](C(N[C@H](C(N7[C@H](C(N8[C@H](C(N[C@H](C(N9[C@H](C(N[C@H](C(N[C@H](C(NCCC(NC([C@@H](CCCNC(N)=N)NC([C@@H](C(C)C)NC([C@@H](CCC%10)N%10C([C@@H](CCCNC(N)=N)NC([C@@H](CCC%11)N%11C([C@@H](CCC%12)N%12C([C@@H](CCCNC(N)=N)NC([C@@H](CCC%13)N%13C([C@@H](CCCNC(N)=N)NC([C@@H](CCC%14)N%14C([C@@H](CC(C)C)NC([C@@H](CC%15=CC=C(O)C=C%15)NC([C@@H](CCC%16)N%16C([C@@H](CCCNC(N)=N)NC([C@@H](CCC%17)N%17C([C@@H](CCCCN)NC([C@@H](CC(O)=O)NC([C@@H](CCC%18)N%18C([C@H](NC(C%19(CCCCC%19)N)=O)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C(O)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CCC9)=O)CCCNC(N)=N)=O)CCC8)=O)CCC7)=O)CCCNC(N)=N)=O)CCC6)=O)CCCNC(N)=N)=O)CCC5)=O)CC(C)C)=O)CC%20=CC=C(O)C=C%20)=O)CCC4)=O)CCCNC(N)=N)=O)CCC3)=O)CCCCN)=O)CC(O)=O)=O)CCC2

[1]Li W, et al. Proline-rich antimicrobial peptides: potential therapeutics against antibiotic-resistant bacteria. Amino Acids. 2014 Oct;46 (10) :2287-94. |[2]Ostorhazi E, et al. Rapid systemic and local treatments with the antibacterial peptide dimer A3-APO and its monomeric metabolite eliminate bacteria and reduce inflammation in intradermal lesions infected with Propionibacterium acnes and meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2013 Dec;42 (6) :537-43.